1. Home
  2. LPTH vs GERN Comparison

LPTH vs GERN Comparison

Compare LPTH & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo LightPath Technologies Inc.

LPTH

LightPath Technologies Inc.

HOLD

Current Price

$9.82

Market Cap

1.1B

Sector

Technology

ML Signal

HOLD

Logo Geron Corporation

GERN

Geron Corporation

HOLD

Current Price

$1.24

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LPTH
GERN
Founded
1985
1990
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.0B
IPO Year
2011
1996

Fundamental Metrics

Financial Performance
Metric
LPTH
GERN
Price
$9.82
$1.24
Analyst Decision
Strong Buy
Hold
Analyst Count
3
3
Target Price
$13.33
$2.17
AVG Volume (30 Days)
3.4M
8.5M
Earning Date
05-14-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
51.85
EPS
N/A
N/A
Revenue
$37,202,630.00
$1,065,000.00
Revenue This Year
$83.04
$26.91
Revenue Next Year
$24.83
$43.75
P/E Ratio
N/A
N/A
Revenue Growth
17.26
N/A
52 Week Low
$5.83
$1.04
52 Week High
$18.94
$2.01

Technical Indicators

Market Signals
Indicator
LPTH
GERN
Relative Strength Index (RSI) 44.13 N/A
Support Level $8.96 N/A
Resistance Level $10.96 N/A
Average True Range (ATR) 0.58 0.00
MACD 0.10 0.00
Stochastic Oscillator 56.64 0.00

Price Performance

Historical Comparison
LPTH
GERN

About LPTH LightPath Technologies Inc.

LightPath Technologies Inc manufactures, distributes, and integrates proprietary optical components and assemblies. It develops optical solutions for traditional optics and communications markets. The company's products include precision molded optics and infrared products, serving markets such as distribution, laser, industrial, instrumentation, telecommunications, and defense. Its products are categorized as infrared components, visible components, assemblies and modules, and engineering services. G5 Infrared's revenue mainly comes from infrared components and assemblies.

About GERN Geron Corporation

Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.

Share on Social Networks: